1. Search results in the navigational tree (All hits)
All the results are highlighted by color in the navigational tree
(at the left-hand side) and remain so until you click on a not highlighted menu item and
thus return to the usual content navigation.
In addition, you can browse through the search
results consecutively by pressing the navigational buttons
(
<
1 of
10
>).
Within the text the search
result is highlighted by color.
2. Search results by relevance (Top 5)
Following is a list of the 5 most important hits ranked by relevance.
Hint: In the
Help you will find explanations about using search operators in order to conduct an extended search.
[...] Research and development –296.1 –325.9 –620.3 –628.7 –4.3 –4.5 –8.3 –9.4 Operating result (EBIT)1 282.5 14.0 477.8 175.5 18.1 10.5 29.9 16.2 Depreciation and amortization 206.1 221.0 415.9 443.7 2.0 2.9 4.7 5.9 Impairment losses 5.5 23.2 33.8 32.3 0.3 – 0.2 – Other –0.3 – –0.3 – – – – – EBITDA1 493.8 258.2 927.1 651.4 20.4 13.4 34.8 22.1 One-time items –2.9 191.5 26.5 201.2 –1.1 5.2 –1.2 5.9 EBITDA pre one-time items (Segment result)1 490.9 449.7 953.6 852.7 19.3 18.6 33.6 28.0 EBITDA margin pre one-time items (% of sales)1 32.1 29.1 31.9 28.8 16.7 15.4 14.5 12.2 Net operating assets2 7,538.3 8,020.6 294.7 283.8 Segment [...]
[...] 1,623.8 1,648.6 –1.5% 3,171.4 3,143.9 0.9% Sales 1,530.8 1,546.5 –1.0% 2,985.1 2,963.7 0.7% Operating result (EBIT) 282.5 14.0 n.m. 477.8 175.5 172.3% Margin (% of sales) 18.5% 0.9% 16.0% 5.9% EBITDA 493.8 258.2 91.3% 927.1 651.4 42.3% Margin (% of sales) 32.3% 16.7% 31.1% 22.0% EBITDA pre one-time items 490.9 449.7 9.2% 953.6 852.7 11.8% Margin (% of sales) 32.1% 29.1% 31.9% 28.8% The division’s cost of sales fell by –10.6% to € 283 million in the second quarter of 2013 (Q2 2012: € 317 million). Consequently, cost of sales declined more than sales as a result of an improved product mix and higher biotech production yields. Despite lower royalty, [...]
[...] Total revenues 116.8 121.6 –3.9% 233.1 229.6 1.5% Sales 115.6 121.1 –4.5% 231.8 228.7 1.3% Operating result (EBIT) 18.1 10.5 72.8% 29.9 16.2 84.8% Margin (% of sales) 15.7% 8.7% 12.9% 7.1% EBITDA 20.4 13.4 52.3% 34.8 22.1 57.9% Margin (% of sales) 17.7% 11.1% 15.0% 9.6% EBITDA pre one-time items 19.3 18.6 3.9% 33.6 28.0 20.3% Margin (% of sales) 16.7% 15.4% 14.5% 12.2% At € 37 million, cost of sales were slightly lower than in the year-earlier quarter. Since sales declined as well, gross profit fell by –5.0% to € 79 million (Q2 2012: € 83 million), resulting in a gross margin of 68.6% (Q2 2012: 68.9%). Consumer Health succeeded in sustainably improving [...]
[...] value chain, was the primary contributor of the top line growth in the second quarter 2013. As a result of higher volumes, Process Solutions reported organic sales growth of 7.7% reaching sales of € 277 million (Q2 2012: € 262 million). Therefore, the business unit now accounts for 42% of the division’s sales (Q2 2012: 40%). The increase was driven by higher demand for products used in biopharmaceutical production as well as the business unit’s biodevelopment services that promote single-use manufacturing (for example Mobius®). Growth was also fueled by the very positive development of sales to the pharmaceutical industry during the quarter, especially in [...]
[...] 2,841.1 2,852.1 –0.4% 5,601.6 5,497.1 1.9% Sales 2,743.9 2,743.1 – 5,404.3 5,307.0 1.8% Operating result (EBIT) 465.4 23.2 n.m. 864.8 333.8 159.1% Margin (% of sales) 17.0% 0.8% 16.0% 6.3% EBITDA 793.1 375.0 111.5% 1,546.9 1,028.3 50.4% Margin (% of sales) 28.9% 13.7% 28.6% 19.4% EBITDA pre one-time items 826.4 746.6 10.7% 1,627.5 1,420.9 14.5% Margin (% of sales) 30.1% 27.2% 30.1% 26.8% EPS pre one-time items (€) 2.26 1.92 17.7% 4.37 3.58 22.1% Free cash flow 549.6 625.7 –12.1% 988.2 1,045.4 –5.5% Merck’s solid business performance since the beginning of the year continued in the second quarter of 2013 with total revenues increasing organically by [...]
